We are live on
!
Find out more
PIM
Partner Investment Management Portfolio holdings
AUM
$13.9M
Turnover
66.25%
1-Year Est. Return
55.92%
This Fund
S&P 500
This Quarter
Est. Return
+10.2%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$61M
AUM Growth
-$5.18M
(-7.8%)
Cap. Flow
-$7.91M
Cap. Flow
% of AUM
-12.97%
Top 10 Holdings %
Top 10 Hldgs %
40.21%
Holding
93
New
23
Increased
18
Reduced
20
Closed
29
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$1.7M |
| 2 |
Amazon
AMZN
|
+$1.55M |
| 3 |
Charles Schwab
SCHW
|
+$1.47M |
| 4 |
Alibaba
BABA
|
+$1.38M |
| 5 |
Synchrony
SYF
|
+$1.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.87M |
| 2 |
UnitedHealth
UNH
|
+$2.81M |
| 3 |
HCA Healthcare
HCA
|
+$2.53M |
| 4 |
Gilead Sciences
GILD
|
+$2.26M |
| 5 |
Eli Lilly
LLY
|
+$1.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.96% |
| 2 | Technology | 8.38% |
| 3 | Industrials | 7.42% |
| 4 | Financials | 7.32% |
| 5 | Communication Services | 6.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Walgreens Boots Alliance
WBA
| $3.96M | 6.5% |
46,558
+4,765
| +11% | +$405K |
2014 Q4
4 quarters
|
|
2
Bristol-Myers Squibb
BMY
$124B
| $3.37M | 5.52% |
48,922
+14,279
| +41% | +$944K |
2015 Q1
3 quarters
|
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $3.05M | 5.01% |
9,769
-2,016
| -17% | -$600K |
2015 Q3
1 quarter
|
|
4
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| $2.49M | 4.09% |
37,993
+7,801
| +26% | +$482K |
2014 Q1
7 quarters
|
|
5
Palo Alto Networks
PANW
$303B
| $2.42M | 3.96% |
82,314
+28,854
| +54% | +$833K |
2014 Q2
6 quarters
|
|
6
AerCap
AER
$22.9B
| $2.11M | 3.46% |
48,829
+14,266
| +41% | +$597K |
2015 Q1
3 quarters
|
|
7
Edwards Lifesciences
EW
$50.8B
| $1.86M | 3.04% |
70,482
-20,730
| -23% | -$538K |
2014 Q4
4 quarters
|
|
|
MDCO
8
DELISTED
Medicines Co
MDCO
| $1.81M | 2.97% |
48,493
+12,094
| +33% | +$457K |
2015 Q2
2 quarters
|
|
|
9
Alphabet (Google) Class A
GOOGL
$4.27T
| $1.79M | 2.93% |
+45,960
| New | +$1.7M |
2015 Q4
0 quarters
|
|
|
10
Amazon
AMZN
$2.75T
| $1.66M | 2.72% |
+49,140
| New | +$1.55M |
2015 Q4
0 quarters
|
|
11
Vulcan Materials
VMC
$32.7B
| $1.62M | 2.66% |
17,096
+1,752
| +11% | +$170K |
2014 Q1
7 quarters
|
|
12
Jazz Pharmaceuticals
JAZZ
$13.9B
| $1.55M | 2.55% |
11,044
+2,908
| +36% | +$403K |
2015 Q1
3 quarters
|
|
|
13
Charles Schwab
SCHW
$163B
| $1.53M | 2.51% |
+46,441
| New | +$1.47M |
2015 Q4
0 quarters
|
|
|
14
Alibaba
BABA
$276B
| $1.43M | 2.35% |
+17,610
| New | +$1.38M |
2015 Q4
0 quarters
|
|
15
Universal Health Services
UHS
$11B
| $1.39M | 2.28% |
11,628
+635
| +6% | +$77.6K |
2015 Q2
2 quarters
|
|
16
Heron Therapeutics
HRTX
$71.5M
| $1.25M | 2.05% |
46,938
-5,009
| -10% | -$134K |
2015 Q2
2 quarters
|
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.24M | 2.03% |
35,300
-11,979
| -25% | -$773K |
2013 Q2
10 quarters
|
|
|
ALDR
18
DELISTED
Alder Biopharmaceuticals
ALDR
| $1.21M | 1.99% |
36,756
+13,831
| +60% | +$468K |
2014 Q2
6 quarters
|
|
|
AERI
19
DELISTED
Aerie Pharmaceuticals
AERI
| $1.21M | 1.98% |
49,556
-170
| -0.3% | -$3.97K |
2015 Q1
3 quarters
|
|
|
AET
20
DELISTED
Aetna Inc
AET
| $1.2M | 1.96% |
11,075
-2,815
| -20% | -$304K |
2015 Q2
2 quarters
|
|
|
ACOR
21
DELISTED
Acorda Therapeutics
ACOR
| $1.2M | 1.96% |
233
+49
| +27% | +$214K |
2014 Q3
5 quarters
|
|
22
Textron
TXT
$12.9B
| $1.1M | 1.81% |
26,272
+20,373
| +345% | +$842K |
2015 Q3
1 quarter
|
|
|
23
CALL
Bristol-Myers Squibb
BMY
$124B
| $1.1M | 1.81% |
16,000
-29,100
| -65% | -$1.92M |
2015 Q3
1 quarter
|
|
24
Lam Research
LRCX
$347B
| $1.07M | 1.75% |
+134,420
| New | +$1.01M |
2015 Q4
0 quarters
|
|
|
25
Synchrony
SYF
$24.1B
| $1M | 1.64% |
+32,910
| New | +$1.03M |
2015 Q4
0 quarters
|
|
Similar funds
SWM
ACM
ECAU
SL
DII
FIM
EM
BHC
Partner Investment Management's Q4 2015 Portfolio in Review
As of Q4 2015, Partner Investment Management held 93 positions worth $61M, down 7.8% from $66.2M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Partner Investment Management withdrew a net $7.91M in Q4 2015, closing 29 positions and reducing 20 holdings. Its most notable exit was Pfizer, an estimated $2.87M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 69% a quarter earlier, followed by Technology and Industrials.
Against the trend, Partner Investment Management opened a new position in Alphabet (Google) Class A worth $1.79M.
- Partner Investment Management's largest Q4 2015 buy was Alphabet (Google) Class A: 45,960 shares worth $1.79M.
- Partner Investment Management added most to Bristol-Myers Squibb in Q4 2015, an estimated $944K increase.
- Partner Investment Management's biggest Q4 2015 reduction was UnitedHealth, cutting an estimated $2.81M.
- Partner Investment Management fully exited Pfizer in Q4 2015, selling an estimated $2.87M.
- Partner Investment Management's ten largest holdings make up 40% of its $61M portfolio in Q4 2015.
- Partner Investment Management opened 23 new positions and closed 29 in Q4 2015.
- Partner Investment Management's portfolio value fell 7.8% quarter-over-quarter to $61M.
Based on Partner Investment Management's 13F filing for Q4 2015, filed 16 Feb 2016.